Should You Hold Immunovant (IMVT)?

16h ago, source: InvestingChannel on MSN

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A ...

Here's Why You Should Add Immunovant (IMVT) to Your Portfolio

2d ago, source:

Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are ...

Buy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy Confidence

2d ago, source:

Analyst Derek Archila from Wells Fargo maintained a Buy rating on Immunovant (IMVT – Research Report) and keeping the price target at ...

Immunovant Inc IMVT

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks

1mon ago, source: Nasdaq

A downtrend has been apparent in Immunovant, Inc. (IMVT) lately with too much selling pressure. The stock has declined 8% over the past four weeks. However, given the fact that it is now in ...

Immunovant Awarded U.S. Patent for IMVT-1402

1mon ago, source: Stockhouse

Composition of matter patent issued with coverage until June 2043 Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. ...

Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials

1mon ago, source: Business Insider

Begin your TipRanks Premium journey today. Immunovant (IMVT) Company Description: Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients ...

Immunovant Stock (NASDAQ:IMVT), Quotes and News Summary

1mon ago, source: Benzinga.com

Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following ...

Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?

1mon ago, source: Yahoo Finance

It has been about a month since the last earnings report for Immunovant, Inc. (IMVT). Shares have lost about 14.7% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Here's Why You Should Add Immunovant (IMVT) to Your Portfolio

2d ago, source: Nasdaq

Immunovant, Inc. IMVT is a New York-based biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. The company currently has no marketed products ...